Adverse Outcomes Increased With Long-Term Inhaled Corticosteroids in COPD
By Elana Gotkine HealthDay Reporter
FRIDAY, March 28, 2025 -- For patients with chronic obstructive pulmonary disorder (COPD), long-term inhaled corticosteroid (ICS) treatment is associated with increased rates of adverse composite and specific individual outcomes, according to a study published in the March/April issue of the Annals of Family Medicine.
Wilson D. Pace, M.D., from DARTNet Institute in Aurora, Colorado, and colleagues examined electronic health record data for individuals older than 45 years with COPD to assess long-term ICS risks. The prevalent cohort had a COPD diagnosis any time during the observation period (318,385 individuals), and the inception cohort had a COPD diagnosis after entry into the database (209,062 individuals). A composite outcome of any new diagnosis of type 2 diabetes, cataracts, pneumonia, osteoporosis, or nontraumatic fracture and recurrent event outcomes of repeated pneumonia or nontraumatic fracture were compared for long- versus short-term ICS exposure (>24 months versus <4 months).
The researchers found that the composite dichotomous outcome was significantly greater for long- versus short-term ICS use for both the prevalent and inception cohorts (hazard ratios, 2.65 and 2.60, respectively). The absolute risk difference of the composite outcome was 20.26 percent for the inception cohort, with a number needed to harm of five. For recurrent pneumonia and recurrent fracture, the hazard ratios were significantly increased in the prevalent and inception cohorts (hazard ratios, 2.88 and 2.85 for pneumonia, respectively; 1.77 and 1.57 for fracture, respectively).
"The clinical use of and indications for ICS therapy in COPD should be carefully considered for each individual before initiation of long-term ICS therapy," the authors write.
Several authors disclosed ties to the pharmaceutical industry, and the study was funded by a research grant from Boehringer Ingelheim.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted March 2025
Read this next
ACP: AI Recommendations More Often Better Quality for Virtual Care Visits
MONDAY, April 7, 2025 -- Artificial intelligence (AI) recommendations are more often rated as better quality than final recommendations of physicians for virtual care visits made...
COPD Tied to Increased Risk for Death in Patients With Arthritis
THURSDAY, March 20, 2025 -- Adults with arthritis and chronic obstructive pulmonary disease (COPD) have a higher risk for mortality than individuals without COPD, according to a...
Certain Glucose-Lowering Meds Associated With Lower Risk for COPD Exacerbations
FRIDAY, Feb. 21, 2025 -- For patients with type 2 diabetes (T2D) and chronic obstructive pulmonary disorder (COPD), sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.